Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2010 - 2026)

Acadia Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $66.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 153.43% year-over-year to $66.3 million; the TTM figure through Mar 2026 stood at -$112.2 million (up 20.15% YoY), while the FY2025 annual figure was -$302.6 million, down 890.78% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $66.3 million, up from -$55.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $192.5 million in Q1 2023, with the low at -$194.3 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$17.7 million (2022), against an average of -$9.5 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 35301.73% in 2024, then slumped 783.6% in 2025.
• Acadia Pharmaceuticals' Cash from Investing Activities stood at -$17.7 million in 2022, then soared by 98.04% to -$347000.0 in 2023, then soared by 35301.73% to $122.2 million in 2024, then sank by 145.74% to -$55.9 million in 2025, then surged by 218.64% to $66.3 million in 2026.
• Business Quant data shows ACAD's Cash from Investing Activities at $66.3 million in Q1 2026, -$55.9 million in Q4 2025, and -$79.4 million in Q3 2025.